NEW YORK--(EON: Enhanced Online News)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sinovac Biotech Ltd. (NASDAQ: SVA) resulting from allegations that Sinovac may have issued materially misleading business information to the investing public.
On December 21, 2016, an article published on SeekingAlpha.com revealed that according to a recent Beijing court judgment, the Chairman and CEO of Sinovac, Weidong Ying, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, and his wife, in order to help advance drug applications and evaluations.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Sinovac investors. If you purchased shares of Sinovac, please visit the firm’s website at http://www.rosenlegal.com/cases-1015.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.